RxDoctor Payments Data

Rachel Mindin, OD

Optometrist · Brooklyn, NYNPI 1790331007

Payments from drug & device makers

$2,020in general payments, 2019–2025

Across 94 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$338
  • Sun Pharmaceutical Industries Inc.$312
  • Harrow Eye, LLC$304
  • Bausch & Lomb Americas Inc.$238
  • Novartis$213
  • Tarsus Pharmaceuticals, Inc.$171
  • plus $445 from 10 others

What the payments were for

  • Food & beverage$1,98698%
  • Entertainment$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,020 in reported general payments places this provider in the 75th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$144,974
Medicare patients
191
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine145$92,778
XiidraLifitegrast54$38,611
Cyclosporine62$21,851
Restasis MultidoseCyclosporine27$20,750
MieboPerfluorohexyloctane/Pf22$16,525
VyzultaLatanoprostene Bunod38$13,430
LumiganBimatoprost20$4,841
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$4,556
Prednisolone Acetate111$4,336
Lotemax SmLoteprednol Etabonate12$4,213
Loteprednol Etabonate22$3,832
SimbrinzaBrinzolamide/Brimonidine Tart13$2,595
Brimonidine Tartrate29$2,574
Cosopt PfDorzolamide/Timolol/Pf12$2,213
Fluorometholone21$1,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan$18$118,369192 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$238$68,565114 claims
AlconSimbrinza$338$2,59513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,743 optometrist providers in New York.

Other optometrist in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →